ANI Pharmaceuticals (NASDAQ:ANIP) Stock Passes Below Fifty Day Moving Average – Here’s What Happened

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) passed below its fifty day moving average during trading on Monday . The stock has a fifty day moving average of $81.82 and traded as low as $81.11. ANI Pharmaceuticals shares last traded at $81.33, with a volume of 774,567 shares traded.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on ANIP shares. Weiss Ratings reiterated a “hold (c+)” rating on shares of ANI Pharmaceuticals in a research note on Monday, December 29th. Truist Financial increased their target price on shares of ANI Pharmaceuticals from $77.00 to $90.00 and gave the company a “hold” rating in a research report on Thursday, October 9th. Barclays started coverage on shares of ANI Pharmaceuticals in a research note on Tuesday, December 9th. They set an “overweight” rating and a $100.00 price target on the stock. Zacks Research downgraded shares of ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, January 6th. Finally, Guggenheim raised their price objective on ANI Pharmaceuticals from $115.00 to $124.00 and gave the stock a “buy” rating in a report on Friday, January 16th. Six research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, ANI Pharmaceuticals presently has an average rating of “Moderate Buy” and an average target price of $103.43.

ANI Pharmaceuticals Price Performance

The company has a debt-to-equity ratio of 1.20, a current ratio of 2.58 and a quick ratio of 2.04. The company has a 50 day moving average price of $81.82 and a 200 day moving average price of $84.78. The firm has a market cap of $1.83 billion, a PE ratio of 49.90 and a beta of 0.51.

ANI Pharmaceuticals (NASDAQ:ANIP) last announced its quarterly earnings data on Friday, November 7th. The specialty pharmaceutical company reported $2.04 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.74 by $0.30. ANI Pharmaceuticals had a net margin of 4.91% and a return on equity of 26.73%. The company had revenue of $227.81 million for the quarter, compared to analysts’ expectations of $211.92 million. During the same period in the previous year, the company posted $1.34 EPS. ANI Pharmaceuticals’s revenue was up 53.6% compared to the same quarter last year. ANI Pharmaceuticals has set its FY 2025 guidance at 7.370-7.640 EPS. Sell-side analysts expect that ANI Pharmaceuticals, Inc. will post 3.86 EPS for the current fiscal year.

Insider Transactions at ANI Pharmaceuticals

In other news, SVP Krista Davis sold 1,622 shares of the firm’s stock in a transaction that occurred on Thursday, December 18th. The stock was sold at an average price of $82.40, for a total value of $133,652.80. Following the completion of the sale, the senior vice president directly owned 58,564 shares of the company’s stock, valued at $4,825,673.60. This trade represents a 2.69% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Chad Gassert sold 14,642 shares of ANI Pharmaceuticals stock in a transaction that occurred on Wednesday, November 12th. The shares were sold at an average price of $89.07, for a total value of $1,304,162.94. Following the completion of the sale, the senior vice president owned 158,584 shares in the company, valued at approximately $14,125,076.88. This trade represents a 8.45% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 28,101 shares of company stock valued at $2,453,063 over the last 90 days. Insiders own 12.70% of the company’s stock.

Institutional Investors Weigh In On ANI Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Arrowstreet Capital Limited Partnership acquired a new position in shares of ANI Pharmaceuticals during the 3rd quarter worth $32,992,000. Balyasny Asset Management L.P. boosted its holdings in ANI Pharmaceuticals by 2,785.7% during the third quarter. Balyasny Asset Management L.P. now owns 286,149 shares of the specialty pharmaceutical company’s stock worth $26,211,000 after buying an additional 276,233 shares in the last quarter. Divisadero Street Capital Management LP acquired a new position in ANI Pharmaceuticals during the third quarter worth about $21,454,000. Rubric Capital Management LP increased its holdings in ANI Pharmaceuticals by 354.7% in the second quarter. Rubric Capital Management LP now owns 257,669 shares of the specialty pharmaceutical company’s stock valued at $16,813,000 after buying an additional 200,998 shares in the last quarter. Finally, UBS Group AG increased its holdings in ANI Pharmaceuticals by 45.8% in the third quarter. UBS Group AG now owns 589,874 shares of the specialty pharmaceutical company’s stock valued at $54,032,000 after buying an additional 185,172 shares in the last quarter. Institutional investors and hedge funds own 76.05% of the company’s stock.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.